Share

In This Section

FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma

On October 13, the US Food and Drug Administration (FDA) approved nivolumab for the adjuvant treatment of completely resected Stage IIB/C melanoma in patients 12 years and older.

For more information read the FDA announcement and the Bristol-Myers Squibb announcement. 

Posted 10/16/2023